Since JAK2 mutations constitutively activate downstream signaling and are drivers of myeloproliferative neoplasm [21], the discovery of specific inhibitors of the JAK2 protein has become a research hotspot for the treatment of diseases. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.